LAT and non-small cell lung carcinoma: Another randomised phase II trial in oligometastatic NSCLC patients with 1–5 metastases also showed that LAT to all sites of disease after systemic therapy is associated with a significant improvement in PFS compared with maintenance therapy alone [6].